INTRAVITREAL INJECTION OF THERAPEUTIC AGENTS
The DOI matches its Crossref record; 525 of the 536 references it cites were found in a registry or an index.
Abstract
In Brief Background: Intravitreal injection (IVI) with administration of various pharmacological agents is a mainstay of treatment in ophthalmology for endopthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, vascular occlusions, and retinal detachment. The indications and therapeutic agents are reviewed in this study. Methods: A search of the English, German, and Spanish language MEDLINE database was conducted. A total of 654 references spanning the period through early 2008 were individually evaluated. Results: The advantage of the IVI technique is the ability to maximize intraocular levels of medications and to avoid the toxicities associated with systemic treatment. Intravitreal injection has been used to deliver several types of pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, anticancer agents, gas, antivascular endothelial growth factor, and several others. The goal of this review is to provide a detailed description of the properties of numerous therapeutic agents that can be delivered through IVI, potential complications of the technique, and recommendations to avoid side effects. Conclusion: The IVI technique is a valuable tool that can be tailored to the disease process of interest based on the pharmacological agent selected. This review provides the reader with a comprehensive summary of the IVI technique and its multitude of uses. Intravitreal injection has been used to deliver numerous pharmacological agents into the vitreous cavity: antiinfective and antiinflammatory medications, immunomodulators, antineoplastic agents, gas, antivascular endothelial growth factor, and others. In this review, we describe the properties of many intravitreal therapeutic agents, the technique of intravitreal injection, complications, recommendations to avoid side effects, and future trends.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although rates of intraocular inflammation related to intravitreal injection remain relatively low, the overall burden on patients remains a key concern with millions of injections performed every year [85].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [85]
Citations
Cites
The biology of VEGF and its receptors
Ferrara, N., Gerber, H.-P., & LeCouter, J. (2003) · Nature Medicine · doi:10.1038/nm0603-669 · Cited by 9,591
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Promotion of microtubule assembly in vitro by taxol
SCHIFF, P. B., FANT, J., & HORWITZ, S. B. (1979) · Nature · doi:10.1038/277665a0 · Cited by 3,600
Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa062655 · Cited by 3,522
Virus interference. I. the interferon
Isaacs, A., & Lindenmann, J. (1957) · Proceedings of the Royal Society of London. Series B - Biological Sciences · doi:10.1098/rspb.1957.0048 · Cited by 3,451
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
Effects of cytochalasin and phalloidin on actin.
Cooper, J. A. (1987) · The Journal of cell biology · doi:10.1083/jcb.105.4.1473 · Cited by 2,009
Guba, M., von Breitenbuch, P., Steinbauer, M., Koehl, G., Flegel, S., Hornung, M., Bruns, C. J., Zuelke, C., Farkas, S., Anthuber, M., et al. (2002) · Nature Medicine · doi:10.1038/nm0202-128 · Cited by 1,739
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Research works printed but not linked: 8
- Komoto, 1912, Ueber Glaskorperwaschung bei unheilbarer Glaskorperblutung., KIin Monatsbl Augenheilkd, 50, 265
- Lowenstein, 1912, Uber Glaskorperersatz: 1.Teil: Experimentelle Untersuchungen., Albrecht von Graefes Arch Ophthalmol, 80, 500
- Zirm, 1925, Ein Beitrag zur Glaskorperabsaugung., Klin Monatsbl Augenheilkd, 75, 730
- Kucers, 1979, The Use of Antibiotics: A Comprehensive Review with Clinical Emphasis. 3rd ed.
- Rosenfeld, 2006, Ranibizumab: phase III clinical trial results., Ophthalmol Clin North Am, 19, 361
- Case, 1985, Clearance of intravitreal 3H-fluorouracil., Ophthalmic Surg, 16, 378
- Pillat, 1956, The aging of the retina., Trans Am Acad Ophthalmol Otolaryngol, 60, 206
- Dominguez, 1985, Cirugia precoz y ambulatoria del desprendimento de retina. (Spanish)., Arch Soc Esp Oftalmol, 48, 47
Cited by
Items 101–200 of 258
Targeted Drug Delivery to the Eye Enabled by Microneedles
Patel, S. R., Edelhauser, H. F., & Prausnitz, M. R. (2011) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4419-9920-7_14 · Cited by 22
“This lack of targeting is generally a concern for all approaches that release drugs into the vitreous, including intravitreal injections that have become a common method to deliver drugs to the back of the eye ( Peyman et al. 2009 ).”
MethodTower microneedle minimizes vitreal reflux in intravitreal injection
Lee, C. Y., You, Y. S., Lee, S. H., & Jung, H. (2013) · Biomedical Microdevices · doi:10.1007/s10544-013-9771-y · Cited by 21
“The IVT by hypodermic needle, however, may result in serious surgical trauma, such as hemorrhage, retinal detachment, endophthalmitis, and cataracts (Jager et al. 2004; Peyman et al. 2009).”
Shortening Ocular Pain Duration following Intravitreal Injections
Rifkin, L. M., & Schaal, S. (2012) · European Journal of Ophthalmology · doi:10.5301/ejo.5000147 · Cited by 21
“tory, anticancer, anti-VEGF medications, as well as gas into the eye (1).”
BackgroundThe Intervention of Nanotechnology Against Epithelial Fungal Diseases
Higa, L. H., Schilrreff, P., Perez, A. P., Morilla, M. J., & Romero, E. L. (2012) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2013.1065 · Cited by 22
Utilizing extracellular vesicles as a drug delivery system in glaucoma and RGC degeneration
Durmaz, E., Dribika, L., Kutnyanszky, M., & Mead, B. (2024) · Journal of Controlled Release · doi:10.1016/j.jconrel.2024.06.029 · Cited by 23
“Less commonly observed but more serious complications include retinal toxicity or detachment, corneal abrasions, uveitis, and vitreal or subretinal haemorrhage [116].”
Güzel, H., Bakbak, B., Köylü, M. T., Gönül, Ş., Öztürk, B., & Gedik, Ş. (2016) · Cutaneous and Ocular Toxicology · doi:10.3109/15569527.2016.1140177 · Cited by 20
Advances in nanomedicine-based retinal drug delivery: mechanisms and translational applications
Nafar, H., Sharif, P. M., & Rezaei, N. (2025) · Journal of Nanobiotechnology · doi:10.1186/s12951-025-03848-3 · Cited by 21
Intravitreal injections: A review of pharmacological agents and techniques
Shikari, H., & Samant, P. (2016) · Journal of Clinical Ophthalmology and Research · doi:10.4103/2320-3897.174429 · Cited by 21
“2015 Intravitreal injections were first described at the turn of the 20 century when Deutschmann and Ohm used rabbit vitreous and air to repair retinal detachments in humans.([1,2])”
BackgroundSrirangam, R., Hippalgaonkar, K., & Majumdar, S. (2012) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23047 · Cited by 19
Cheung, C. S. Y., Noordeh, N., & Gottlieb, C. (2016) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-016-0102-3 · Cited by 18
“This observation may be attributable to the rapid increase of intravitreal injections performed for posterior segment diseases in the past decade [14, 15].”
BackgroundWhich quadrant is less painful for intravitreal injection? A prospective study
Karimi, S., Mosavi, S. A., Jadidi, K., Nikkhah, H., & Kheiri, B. (2018) · Eye · doi:10.1038/s41433-018-0208-y · Cited by 18
Quantitative intravitreal pharmacokinetics in mouse as a step towards inter-species translation
Puranen, J., Ranta, V., Ruponen, M., Urtti, A. O., & Sadeghi, A. (2023) · Experimental Eye Research · doi:10.1016/j.exer.2023.109638 · Cited by 18
Intravitreal Injection Therapy in the Treatment of Noninfectious Uveitis
Modorati, G. M., & Miserocchi, E. (2012) · Developments in ophthalmology · doi:10.1159/000336471 · Cited by 17
Challenges in Ocular Pharmacokinetics and Drug Delivery
Macwan, J. S., Hirani, A., & Pathak, Y. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_26 · Cited by 23
Intravitreal Injections of Bevacizumab: The Impact of Needle Size in Intraocular Pressure and Pain
Loureiro, M., Matos, R., Sepúlveda, P., & Meira, D. (2017) · JOURNAL OF CURRENT GLAUCOMA PRACTICE · doi:10.5005/jp-journals-10028-1220 · Cited by 16
Effect of Ketorolac 0.5% Drops on Patients' Pain Perception During Intravitreal Injection Procedure
Georgakopoulos, C. D., Vasilakis, P., Makri, Ο. E., Beredima, E., & Pharmakakis, N. M. (2012) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0023 · Cited by 17
Lamirande, P., Gaffney, E. A., Gertz, M., Maini, P. K., Crawshaw, J. R., & Caruso, A. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.12.21 · Cited by 15
“16 Broad guidelines have been specified; for example, the needle tip should be inserted more than 6 mm aiming at the center of the eye 17 with the bevel facing upward, 18 which provides less than a precise target for the injection site.”
BackgroundRanibizumab Treatment Outcomes in Phakic versus Pseudophakic Eyes
Weinberg, D. V., Shapiro, H., & Ehrlich, J. S. (2013) · Ophthalmology · doi:10.1016/j.ophtha.2012.11.042 · Cited by 14
Al-Rashaed, S., Alsulaiman, S. M., Alrushood, A. A., Almasaud, J. S., & Arévalo, J. F. (2015) · Middle East African Journal of Ophthalmology · doi:10.4103/0974-9233.171756 · Cited by 14
Intravitreal infusion: A novel approach for intraocular drug delivery
Tian, J., Liu, J., Liu, X., Xiao, Y., & Tang, L. (2016) · Scientific Reports · doi:10.1038/srep37676 · Cited by 14
Endoftalmitis tras inyecciones intravítreas. Incidencia, manejo y pronóstico
Tarragó, R., Olea, J. L., Ramírez, C., & Escudero, L. (2016) · Archivos de la Sociedad Española de Oftalmología · doi:10.1016/j.oftal.2016.09.006 · Cited by 18
Park, Y.-H., Shin, J., Park, J., Kim, S., Park, J. H., Kim, J., Kim, C. S., Chang, J. W., Schuurmans, C., Aubert, I., et al. (2024) · Translational Vision Science & Technology · doi:10.1167/tvst.13.5.5 · Cited by 16
“5,6 Delivering therapeutics, such as AuNPs, to the RGC layer using a non-invasive, safe, and efficient method remains an unmet need in the ophthalmic field.”
Macular oedema as manifestation of diabetic retinopathy
Bikbov, M. M., Fayzrakhmanov, R. R., Zainullin, R. M., Zaynetdinov, A. F., Риксович, Г. Т., & Римович, К. М. (2017) · Diabetes Mellitus · doi:10.14341/dm8328 · Cited by 12
Neroev, V. V., Astakhov, Y. S., Korotkih, S. A., Валерьевич, Б. Е., Zaytseva, O. V., Lisochkina, A. B., Af, B., Budzinskaya, M. V., Gatsu, M. V., Grigoryeva, N. N., et al. (2020) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2020136062251 · Cited by 13
Lagstein, O., Cohen, N. B.-A., Achiron, A., Nemet, A., Khreish, M., Bartov, E., & Burgansky–Eliash, Z. (2016) · Retina · doi:10.1097/iae.0000000000001397 · Cited by 13
Chun, L. Y., Dolle-Molle, L., Bethel, C., Dimitroyannis, R. C., Williams, B. L., Schechet, S. A., Hariprasad, S. M., Missiakas, D. M., Schneewind, O., Beavis, K. G., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0227071 · Cited by 13
The Effect of Ocular Pigmentation on Transscleral Delivery of Triamcinolone Acetonide
Du, W., Sun, S., Xu, Y. H., Li, J., Zhao, C., Lan, B., Chen, H., & Cheng, L. (2013) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2012.0226 · Cited by 12
“The route of the intravitreal injection is more invasive and is associated with a higher rate of complications such as vitreous infection, vitreous hemorrhage, cataract, and elevation of intraocular pressure.(5,6) In contrast, the subtenon injection or transscleral delivery has many advantages.”
BackgroundRam, J., Agarwal, A. K., Gupta, A., & Gupta, A. (2012) · BMJ Case Reports · doi:10.1136/bcr-2012-007494 · Cited by 12
Endophthalmitis after intravitreal injections versus cataract surgery: a 15-year cohort
Dar, N., Pillar, S., Friehmann, A., Belkin, A., & Ofir, S. (2019) · International Ophthalmology · doi:10.1007/s10792-019-01153-1 · Cited by 12
Endogenous Endophthalmitis: Etiology and Treatment
Kabbara, S. W., Kelkar, N., Conway, M. D., & Peyman, G. A. (2021) · IntechOpen eBooks · doi:10.5772/intechopen.96766 · Cited by 12
Self-citationA retinal proteomics‐based study identifies αA‐crystallin as a sex steroid‐regulated protein
D’Anna, C., Cascio, C., Cigna, D., Galizzi, G., Deidda, I., Bianchi, L., Russo, D., Passantino, R., Bini, L., & Guarneri, P. (2011) · PROTEOMICS · doi:10.1002/pmic.201000561 · Cited by 13
“Considering the current ophthalmic practice of intravitreal injections for the treatment of vitreoretinal diseases [11], it is also intriguing that these proteins with a proposed role in promoting survival and resistance to cellular stress were upregulated after the vehicle injection.”
BackgroundMethodXiao, J. F., Luo, W., Mani, A., Barba, H., Solanki, A., Droho, S., Lavine, J. A., & Skondra, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252111357 · Cited by 11
Endophthalmitis after intravitreal injections. Incidence, management and prognosis
Tarragó, R., Olea, J. L., Ramírez, C., & Escudero, L. (2017) · Archivos de la Sociedad Española de Oftalmología (English Edition) · doi:10.1016/j.oftale.2016.09.019 · Cited by 15
Makri, Ο. E., Tsapardoni, F. N., Pagoulatos, D. D., Pharmakakis, N. M., & Georgakopoulos, C. D. (2017) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.12988 · Cited by 11
“After the injection, pressure was applied gently at the injection site to limit vitreous reflux with a cotton swab stick, and finally, a drop of antibiotic was instilled.(1)”
BackgroundMethodNanotechnology for ocular and optic drug delivery and targeting
Pakzad, Y., Fathi, M., Omidi, Y., Zamanian, A., & Mozafari, M. (2020) · Elsevier eBooks · doi:10.1016/b978-0-08-102985-5.00021-8 · Cited by 14
Newly-established in vitro inner BRB spheroids to elucidate retinal Ang2-linked substance transfer
Yamamoto, Y., Akanuma, S., Kon, H., Endo, H., Kubo, Y., & Hosoya, K. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.09.019 · Cited by 10
Chaudhari, P., Lewis, S. A., & Ghate, V. (2025) · Contact Lens and Anterior Eye · doi:10.1016/j.clae.2025.102367 · Cited by 11
Assessment of patient pain experience during intravitreal ranibizumab and aflibercept injection
Bilgin, B., & Bilak, Ş. (2019) · Middle East African Journal of Ophthalmology · doi:10.4103/meajo.meajo_90_19 · Cited by 10
Gogoi, N. R., Marbaniang, D., Pal, P., Ray, S., & Mazumder, B. (2022) · Pharmaceutical Nanotechnology · doi:10.2174/2211738510666220806102612 · Cited by 10
Subretinal Delivery of Cells via the Suprachoroidal Space: Janssen Trial
Baldassarre, J. S., Joseph, A., Keane, M. P., & Heier, J. S. (2017) · Springer eBooks · doi:10.1007/978-3-319-49479-1_8 · Cited by 10
Zhdanov, A. E., Dolganov, A. Y., Kazajkin, V. N., Ponomarev, V. O., Lizunov, A. V., Борисов, В., Evdochim, L., Bao, X., & Dorosinskiy, L. G. (2020) · E-Health and Bioengineering Conference (EHB) · doi:10.1109/ehb50910.2020.9280221 · Cited by 11
“Due to the difficulty in assessing the toxic effects of drugs on human eyes, experiments on laboratory animals are used to develop methods for assessing the toxicity of drugs, together with determining the minimum effective concentrations [5, 6].”
MethodNovel oral medications for retinal disease: an update on clinical development
DeBoer, C. M. T., Agrawal, R., & Rahimy, E. (2023) · Current Opinion in Ophthalmology · doi:10.1097/icu.0000000000000948 · Cited by 9
“Furthermore, injections have associated risks such as elevation of intraocular pressure, endophthalmitis, retinal toxicity, central artery occlusion, subconjunctival haemorrhage and floaters [2].”
BackgroundComparison of Two Anesthetic Methods for Intravitreal Ozurdex Injection
Karabas, V. L., Özkan, B., Koçer, Ç. A., Altıntaş, Ö., Pirhan, D., & Yüksel, N. (2015) · Journal of Ophthalmology · doi:10.1155/2015/861535 · Cited by 9
Stability, Formulation, and Delivery of Biopharmaceuticals
Mahler, H., & Allmendinger, A. (2017) · Methods and principles in medicinal chemistry · doi:10.1002/9783527699124.ch14 · Cited by 15
Microneedles for Ocular Drug Delivery and Targeting: Challenges and Opportunities
Tekko, I. A., & Singh, T. R. R. (2018) · Wiley eBooks · doi:10.1002/9781119305101.ch10 · Cited by 9
Yahalomi, T., Hecht, I., Lagstein, O., Nemet, A., Pe’er, L., Hadad, F., Keren-Yaar, A., Kassem, R., Burgansky–Eliash, Z., Bar, A., et al. (2019) · Retina · doi:10.1097/iae.0000000000002608 · Cited by 8
Schaefer, E., Smith, S. M., Salmon, J. H., Abbaraju, S., Amin, R., Weiss, S. L., Grau, U. M., Velagaleti, P., & Gilger, B. C. (2017) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2016.0181 · Cited by 8
Wong, L., Barkam, S., Seal, S., & McGinnis, J. F. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-27378-1_21 · Cited by 8
Introduction to Nanotechnology with Special Reference to Ophthalmic Delivery
Hirani, A., & Pathak, Y. V. (2016) · Springer eBooks · doi:10.1007/978-3-319-29346-2_1 · Cited by 8
Patel, C. V., & Kishore, K. (2017) · Case Reports in Ophthalmological Medicine · doi:10.1155/2017/4613624 · Cited by 8
“The addition of dexamethasone allows for a safe and effective agent with a short half-life [14].”
BackgroundNovel Long-acting Pharmacotherapy for Exudative Age Related Macular Degeneration
Moisseiev, E., & Loewenstein, A. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190123165216 · Cited by 8
Prosperi‐Porta, G., Muirhead, B., & Sheardown, H. D. (2015) · Journal of Biomedical Materials Research Part B Applied Biomaterials · doi:10.1002/jbm.b.33501 · Cited by 8
Lee, S. M., Park, J. H., Jang, C. H., & Byon, I. S. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108614 · Cited by 8
Marques, J. P., Farinha, C., Costa, M. A., Ferrão, Â., Nunes, S. G., & da Silva, R. M. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-015785 · Cited by 7
Ginés, J., Nentwich, M. M., Bedoya, A. H. P., Cibils, P., Esteche, A., Laspina, F., Samudio, M., Fariña, N., & de Kaspar, H. M. (2012) · Der Ophthalmologe · doi:10.1007/s00347-012-2591-2 · Cited by 7
Intravitreal injection of resveratrol inhibits laser-induced murine choroidal neovascularization
Zhang, H., Li, X.-H., Chen, M., & Luo, J. (2020) · International Journal of Ophthalmology · doi:10.18240/ijo.2020.06.05 · Cited by 9
Adak, S., Jadhav, V. S., & Khatri, D. K. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01925-6 · Cited by 11
“Intravitreal injections are one type of drug delivery strategy that requires cautious approaches to avoid infections and retinal injuries [269].”
Tang, M., Zhong, L., Rong, H., Li, K., Ye, M., Peng, J., & Ge, J. (2024) · Experimental Eye Research · doi:10.1016/j.exer.2024.109931 · Cited by 6
Optimizing Lutein Formulations for Targeted Ocular Drug Delivery: In Vitro and In Vivo Insights
Nguyen, D., Sarkar, S., Thrimawithana, T. R., Piva, T. J., Conn, C. E., Luu, C. D., & Huynh, T. T. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c14464 · Cited by 7
Nordin, N. A., Sadikan, M. Z., Lambuk, L., Hashim, S., Airuddin, S., Nasir, N. A. M., Mohamud, R., Ibrahim, J., & Kadir, R. (2024) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgae129 · Cited by 7
Drug Delivery to the Posterior Segment of the Eye: Challenges and Opportunities
Thrimawithana, T. R., Young, S. A., Bunt, C. R., Green, C. R., & Alany, R. G. (2011) · Drug Delivery Letters · doi:10.2174/2210303111101010040 · Cited by 7
“However management of chronic eye diseases require frequent intravitreal injection of therapeutics, which leads to complications such as retinal detachment, endophthalmitis, increased intraocular pressure and haemorrhage [13].”
BackgroundDelivery of Intraocular Triamcinolone Acetonide in the Treatment of Macular Edema
Pickrell, A., Harris, A., Ngo, S. H., Amireskandari, A., Stewart, E., & Siesky, B. A. (2012) · Pharmaceutics · doi:10.3390/pharmaceutics4010230 · Cited by 6
“Additionally, corticosteroids contain certain anti-angiogenic properties that provide further benefit to patients suffering from ME [2].”
BackgroundWang, J., Tao, Y. K., Feng, J., Niu, Y., Liu, J., & Huang, Y. (2019) · RSC Advances · doi:10.1039/c9ra03070k · Cited by 5
Anterior Segment Complications Following Intravitreal Injection
Mackenbrock, L. H. B., Auffarth, G. U., Albrecht, M. C., Naujokaitis, T., Kessler, L. J., Mayer, C. S., & Khoramnia, R. (2024) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2349-2224 · Cited by 5
Effect of Penetration Angle and Velocity During Intravitreal Injection on Pain
Sternfeld, A., Schaap‐Fogler, M., Dotan, A., Alaa, B., Megiddo, E., Ehrlich, R., & Livny, E. (2021) · Seminars in Ophthalmology · doi:10.1080/08820538.2021.1906914 · Cited by 5
New Ocular Drug Delivery Systems
Kang‐Mieler, J. J., Rudeen, K. M., Liu, W., & Mieler, W. F. (2020) · Springer eBooks · doi:10.1007/978-981-15-7644-7_41 · Cited by 5
Havuz, E., Havuz, S. G., & Gökmen, O. (2020) · European Journal of Ophthalmology · doi:10.1177/1120672120977820 · Cited by 5
Kazaykin, V. N., Ponomarev, V. O., Lizunov, A. V., Zhdanov, A. E., Dolganov, A. Y., & Борисов, В. (2020) · Ophthalmology in Russia · doi:10.18008/1816-5095-2020-4-669-675 · Cited by 6
You, S., Zhou, H., Yang, S., Wu, S., Chen, X., Zhang, R., Chen, W., Wang, H., & Mo, X. (2023) · Journal of Ocular Pharmacology and Therapeutics · doi:10.1089/jop.2022.0114 · Cited by 4
“8,9 However, the chronic and progressive nature of posterior eye segment diseases requires frequent injections, which are inconvenient, painful, and invasive, with potential risks of vitreous hemorrhage, retinal detachment, cataract formation, and endophthalmitis.”
Martínez-Vacas, A., Pierdomenico, J. D., Gómez-Ramirez, A. M., Vidal‐Sanz, M., Villegas‐Pérez, M. P., & García‐Ayuso, D. (2024) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.65.4.10 · Cited by 5
Lin, T., Hsieh, Y., Garg, S. J., Chen, L.-J., Chen, K., Wu, W., Lai, C., Hwang, Y., & Kang, E. Y. (2023) · Ophthalmology and Therapy · doi:10.1007/s40123-023-00659-3 · Cited by 4
A Minimally Invasive Jet Injector for Intravitreal and Subconjunctival Injection
Peyman, G. A., Hosseini, K., & Cormier, M. (2012) · Ophthalmic surgery, lasers & imaging retina · doi:10.3928/15428877-20111129-05 · Cited by 4
Self-citationControlled and sustained release of a corticosteroid drug from block copolymers synthetized by ATRP
Valenti, G., Carta, S. L., Mazzotti, G., Rapisarda, M., Perna, S., Gesù, R. D., Giorgini, L., Carbone, D. C., Recca, G., & Rizzarelli, P. (2017) · Polymer Engineering and Science · doi:10.1002/pen.24557 · Cited by 4
Karakahya, R. H. (2021) · Cureus · doi:10.7759/cureus.20051 · Cited by 3
“Introduction Intravitreal injections (IVI), maximizing the intraocular concentrations while minimizing the systemic exposure, has become the standard procedure in ophthalmologic conditions such as endophthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis,…”
BackgroundImpact of Intravitreal Anti–VEGF Injections on Cataract Development
Choi, J., Choi, E. J., Kang, W., Kim, S. S., Hwang, S., & Lee, H. (2026) · Ophthalmology · doi:10.1016/j.ophtha.2026.03.009 · Cited by 3
Obstruction and Approaches to Cross the Drug Molecules through Blood Retinal Barrier: An Overview
Seethamraju, S. M., & Nori, L. P. (2024) · Pharmacophore · doi:10.51847/tblh98sxcq · Cited by 3
Relationship between Pain and Injection Site during Intravitreal Injection
Jeong, K. D., Kim, J. H., Kim, J. S., & Hwang, J. H. (2016) · Journal of the Korean Ophthalmological Society · doi:10.3341/jkos.2016.57.6.930 · Cited by 3
“J Korean Ophthalmol Soc 2016;57(6):930-934”
Efficacy and safety of intravitreal drug injections using a short 34-gauge needle
Sasajima, H., Tsuboi, K., Murotani, K., & Kamei, M. (2019) · Japanese Journal of Ophthalmology · doi:10.1007/s10384-019-00663-w · Cited by 3
Korotkikh, S. A., Валерьевич, Б. Е., Федорович, Э. В., Malishevskaya, Т. N., Kubareva, I. A., Akulevich, T. G., & Morozova, O. V. (2019) · Ophthalmology Reports · doi:10.17816/ov2019127-36 · Cited by 3
Mani, S., Jin, H. D., Shonka, B., Fortenbach, C. R., & Russell, J. F. (2023) · Journal of VitreoRetinal Diseases · doi:10.1177/24741264231175555 · Cited by 3
Preventing Intraocular Infections after Intravitreal Injections: Injection Technique
Leng, T. (2012) · Clinical Microbiology Open Access · doi:10.4172/2327-5073.1000118 · Cited by 3
“The inferotemporal quadrant of the eye is recommended for IVIs to avoid introducing the medication into the visual axis [20] (some medications like aflibercept and triamcinolone acetonide cause a perceptible floater to be seen by the patient).”
BackgroundAnayol, M. A., Şekeroğlu, M. A., Tırhış, H., Gülpamuk, B., Doğuizi, S., & Yılmazbaş, P. (2016) · Journal of Cataract & Refractive Surgery · doi:10.1016/j.jcrs.2016.08.018 · Cited by 3
“These patients typically require multiple injections over time, proportionally increasing their cumulative risk for developing complications.(11,12) Many of these complications are associated with the injection procedure itself, including retinal tears and detachments, iatrogenic lens damage, vitreous hemorrhage, and…”
BackgroundStandard Operating Procedures for Common Laboratory Animal Ocular Procedures
Gilger, B. C., Bartoe, J. T., Eaton, J. S., & Boyd, R. F. (2018) · Springer eBooks · doi:10.1007/978-3-319-78364-2_2 · Cited by 4
Moshkovsky, R., Golan, N., Gadot, E. A., Bar, A., Achiron, A., Fischer, N., & Spierer, O. (2023) · Acta Ophthalmologica · doi:10.1111/aos.15798 · Cited by 2
Kaur, G., Kar, A., Gupta, G., Sharma, A., Sahebkar, A., Kesharwani, P., & Dandela, R. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13881-2.00009-6 · Cited by 2
Zaman, M., Alowedi, S. A., & Sharma, S. (2025) · Canadian Journal of Ophthalmology · doi:10.1016/j.jcjo.2025.06.003 · Cited by 2
Nanomodification of Chitosan Microspheres with Dendron Molecules
Aldana, A. A., Strumia, M. C., & Martinelli, M. (2012) · Journal of Biomaterials and Tissue Engineering · doi:10.1166/jbt.2013.1075 · Cited by 2
Pharmacokinetics of Povidone-Iodine and Its Effects on Bacterial Keratitis
Aziztama, R. (2021) · Sriwijaya Journal of Ophthalmology · doi:10.37275/sjo.v4i2.54 · Cited by 2
Neurogenic dry eye associated with intravitreal injection of anti-VEGF agents
Lin, S.-H., Fang, Y., Jia, F.-L., & Li, Y.-J. (2023) · European Journal of Ophthalmology · doi:10.1177/11206721231177475 · Cited by 2
Kıvrak, U., Arsan, A. K., Akçay, G., Bulut, M. N., Kanar, H. S., Hacısalihoğlu, A., & Şimşek, Ş. (2024) · International Ophthalmology · doi:10.1007/s10792-024-03134-5 · Cited by 3
“In conclusion, the intraocular inflammation seen after intravitreal injection is rare but awareness of this entity is crucial since millions of intravitreal injections are made around the world every year [41].”
Multifunctional biomimetic nanosystem for retinoblastoma treatment
Chen, Z., Wei, D., Wang, Q., Gou, Q., Tsauo, J., Mai, Q., Chen, X., Cai, X., Chen, X., & Zhang, J. (2024) · Chemical Engineering Journal · doi:10.1016/j.cej.2024.156017 · Cited by 2
Hösel, K., Chasan, B., Tode, J., Rose‐John, S., Roider, J. B., & Ehlken, C. (2024) · Journal of Ophthalmic Inflammation and Infection · doi:10.1186/s12348-024-00441-x · Cited by 2
“However, intravitreal injections would offer the advantage of achieving a higher drug concentration in the eye while reducing the incidence of systemic side effects [38].”
BackgroundColizzi, B., Romano, D., Lunardon, S., Sabbatini, L., & Rossetti, L. M. (2025) · European Journal of Ophthalmology · doi:10.1177/11206721251318773 · Cited by 2
Clinical update — pharmacological issues in ophthalmology
Amanda, S., & Needham, Y. (2012) · International Journal of Ophthalmic Practice · doi:10.12968/ijop.2012.3.1.43 · Cited by 2
Mimouni, M., Haim, L. N. B., Rozenberg, E., Shapira, Y., Beiran, I., & Zayit‐Soudry, S. (2020) · Retina · doi:10.1097/iae.0000000000002956 · Cited by 2
Effect of Fluid Flow Direction on Intravitreal Injections of Drugs into Eye
Sibak, M. A., Ahmadikia, H., & Babaee, M. (2023) · Heat Transfer Engineering · doi:10.1080/01457632.2023.2249730 · Cited by 2
“Nevertheless, repeated injections of drugs in this way can lead to retinal detachment, retinal hemorrhage, intraocular inflammation, and increased intraocular pressure [9, 10].”
BackgroundIntravitreal injections: A historic background
Peyman, G. A. (2018) · Journal of Ophthalmic and Vision Research · doi:10.4103/jovr.jovr_54_18 · Cited by 2
“Manzano,[16] and some other studies,[17,18] we performed J Ophthalmic Vis Res 2018; 13 (2): 91–92”
ResultSelf-citationSzaflik, J. P., & Szaflik, J. (2010) · Retina · doi:10.1097/iae.0b013e3181e8a5c5 · Cited by 2
Jia, Y., Liu, H., Yuan, Q., Liu, J.-H., Jia, F.-L., Zhang, H., Li, J., & Li, Y.-J. (2022) · Medicine · doi:10.1097/md.0000000000031204 · Cited by 1
“Intravitreal injection can effectively reduce retinal capillary leakage and improve retinal microcirculation.[31,32] VEGF stimulates endothelial production of nitric oxide, which is well documented as a vasodilator.”
BackgroundNanozymes in the Repair of Fundus Damage
Zhang, W., Ji, W., Cheng, M., Xue, H., Peng, C., Li, W., Ma, L., Zhang, W., Ji, X., & Zhang, Z. (2025) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.5c07979 · Cited by 2
Metadata
- Authors
- PEYMAN, G. A., LAD, E. M., & MOSHFEGHI, D. M.
- Affiliations
- University of Arizona (US)
- Stanford University (US)
- Corresponding author
- PEYMAN, GHOLAM A.
- Venue
- Retina
- Published
- 2009-07
- Volume
- 29
- Issue
- 7
- Pages
- 875-912
- ISSN
- 0275-004X (ISSN-L)
- OpenAlex
- W2090780299
- Cited by
- 255
- References
- 536
- Citations by year
- 2026: 11 · 2025: 12 · 2024: 24 · 2023: 15 · 2022: 12 · 2021: 11 · 2020: 15 · 2019: 15 · 2018: 11 · 2017: 19 · 2016: 24 · 2015: 16 · 2014: 18 · 2013: 11 · 2012: 20
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Retina (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Keywords
- intravitreal injection, endophthalmitis, viral retinitis, age-related macular degeneration, cystoid macular edema, diabetic retinopathy, uveitis, retinal detachment, VEGF inhibitors, anti-inflammatory agents, immunomodulators, anticancer agents, gas tamponade, injection complications
- MeSH terms
- Drug Therapy, Humans, Injections, Vitreous Body
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.